efficacy of Shallakyadi capsule Capsule in the management of Post Chikungunya Chronic Inflammatory Rheumatism
Phase 3
- Conditions
- Health Condition 1: A920- Chikungunya virus disease
- Registration Number
- CTRI/2021/04/033079
- Lead Sponsor
- Institute of Teaching and Research in Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Confirm case of Chikungunya fever with symptoms of pCHIK-CIR
Patient willing to participate in the trial
Exclusion Criteria
Age below 18 years & above 60 years.
Pregnant and lactating women
History of RA, Gout, Psoriatic arthritis, rheumatic fever, autoimmune disease, thyroid dysfunction, sarcoidosis, SLE before Chikungunya fever.
Patients suffering from: Malignant and accelerated hypertension, coronary artery disease, uncontrolled diabetes.
Patient undergoing regular treatment for any other severe illness and also patients suffering from pulmonary tuberculosis or bone tuberculosis, carcinoma and HIV positive patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drug will reduce the inflammation and pain through correcting underlined pathogenesis and so that it will become possible to manage Post - Chikungunya Chronic Inflammatory Rheumatism(pCHIK-CIR)Timepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method The drug will improve the quality of life in patient of Post-Chikungunya Chronic Inflammatory RheumatismTimepoint: 8 weeks